Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Van De Velde, L. Crenier, C. De Block, S. Candon, H. Waldmann, A. G. Ziegler, L. Chatenoud, D. Pipeleers

Research output: Contribution to journalArticlepeer-review

276 Scopus citations

Fingerprint

Dive into the research topics of 'Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology